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Effect of a topical corticosteroid, a retinoid and a 
vitamin D3 derivative on sodium dodecyl sulphate 
induced skin irritation
T. K. M. L e , P. d e  M o n , J. S c h a l k w i j k  a n d  P. G. M. v a n  d e r  V a l k  
Department o f Dermatology, University Hospital Nijmegen, The Netherlands
Exposure of the skin to sodium dodecyl sulfate (SDS) leads to disruption of barrier and skin 
irritation. We used repetitive short exposure to a low molarity SDS solution as an in vivo model to 
mimic the development of irritant contact dermatitis. In this model, we studied clinical (erythema), 
functional (transepidermal water loss(TEWL)) and cell biological changes. 24 healthy volunteers 
were patch tested with SDS (0.2%) for 4 h a day for 5 consecutive days. After removal of the 
patches, the exposed sites were treated 1X daily either with a topical corticosteroid (triamcinolon 
acetonide cream 0.05%), a retinoid (tretinoin cream 0.025%), or a vitamin D 3 derivative (calcipotri- 
ol ointment 50 microgram/g). Irritant reactions were assessed by erythema scoring and measure­
ment of barrier function with TEWL up to 14 days after the first challenge. Skin biopsies were 
taken for cell biological changes at day 4. Vehicle-treated sites served as controls. Repetitive ex­
posure of human skin to SDS resulted in a gradual increase in erythema scoring and TEWL 
associated with the upregulation of proliferative cells as measured by the expression of Ki-67- 
antigen and of differentiation markers, visualized by increased expression of involucrin and epider­
mal-fatty-acid binding protein (E-FABP). Skin irritation as assessed by erythema scoring and 
TEWL was not significantly suppressed by triamcinolone cream. However, a significant reduction 
of the number of cycling keratinocytes and a decrease in involucrin positive cell layers was observed 
in this group. Neither treatment with calcipotriol ointment nor with tretinoin cream induced im­
provement of skin irritation as judged by visual scoring and TEWL. In contrast to steroid treat­
ment, no significant effect o f calcipotriol ointment or tretinoin cream treatment was observed with 
regard to the number of cycling cells and differentiation markers. Further studies are needed to 
assess whether treatment with topical corticosteroids is an effective modality in skin irritation and 
irritant contact dermatitis.
Key words: sodium dodecyl sulfate; irritant contact dermatitis; corticosteroids; retinoids; vitamin
D 3 derivatives; treatment; skin irritation. © Munksgaard, 1997.
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Irritant contact dermatitis (ICD) is characterized ling cells and the epidermal differentiation markers
by mild erythema, itosis or dyskeratosis, (involucrin, epidermal fatty acid binding protein
chapping and fissures (1) and is pathogenetically (E-FABP) ) in the irritant reaction
thought to be the results of cumulative exposure to single 4-h exposure to SDS (5%) (w/v) (4). An SDS
irritants which may be o f various origin (2). Daily concentration of 0.2% caused a significant increase
exposure to these irritants cannot be standardized. TEWL any change in
To study the pathogenesis of ICD, experimental epidermal proliferation and different! 
models in men are needed. In vivo models have pared to the normal skin was seen (5)
centration of SDS was chosen in th
A 0.2%
model to avoid severe damage to the skin and
been used to investigate the effects o f the cumula­
tive exposure of human skin to sodium dodecyl 
sulfate (SDS) in terms of erythema, skin dryness mimic daily life exposure. In the model presented, 
and transepidermal water loss (TEWL) (3). Re- we studied the time course of the erythematous re­
ports on cell biological changes in SDS exposed sponse, TEWL and epidermal growth in the irri- 
skin are scarce. Recently, we demonstrated that the tant human skin induced by repeated daily 4-h ex­
development of erythema and TEWL was associ- posures to SDS (0.2%) for 5 consecutive days.
ated with the upregulation of the number of cyc- We postulate that drugs which can influence epi-
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Fig. 1. Time course of erythema from day 0 to day 14. 0, no 
response; 1, slight, patchy redness; 2, diffuse mild redness; 3, 
moderate redness; 4, intense redness; 5, intense redness with 
edema: (A) of the SDS-exposed skin and the triamcinolon- 
treated group versus its vehicle; (B) of the SDS-exposed skin 
and the tretinoin-treated group versus its vehicle; (C) of the 
SDS-exposed skin and the calcipotriol-treated group versus its 
vehicle.
inflammatory conditions (8, 9), is downregulated 
to the normal levels in the steroid-treated epider­
mis (7).
The vitamin A metabolite, retinoic-acid, is es­
sential to normal differentiation of many tissues 
including skin. Retinoic acid and synthetic retin­
oids are used in the treatment of acne (10), pso­
riasis (11) and certain malignancies (12). Several 
studies in mouse and man indicate that topical re­
tinoic acid speeds repair of skin damage due to 
ultraviolet radiation (13, 14). Effects of retinoids 
on the epidermis include modification of keratin 
expression (15) and inhibition of cross-linked 
cornified envelope synthesis (16). Retinoids can 
either stimulate or inhibit cell growth (17).
Vitamin D 3 derivatives are the recent therapeutic 
modalities in psoriasis.They are known to affect 
the epidermal growth. Administration of vitamin 
D 3 to cultured keratinocytes causes suppression of 
cell proliferation and enhancement of cell differen­
tiation (18). Vitamin D 3 derivatives can modulate 
inflammatory processes. When T-lymphocyte cul-
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dermal growth resulting in the improvement of the 
skin barrier function, may be effective in the treat­
ment of ICD. Topical steroid, retinoic acid and vit­
amin D3 derivative are the therapeutic modalities 
used in dermatology to modulate epidermal 
growth and differentiation. They are often used in 
treatment of inflammatory skin disorder like pso­
riasis. Whether they can improve the disruption of 
skin barrier and irritation by irritants is not 
known.
Topical corticosteroids are frequently used in 
ICD (6) due to their anti-inflammatory effects. A 
previous study demonstrated a reduction o f mi- dl d2 d3 d4 as d6 d7 dl° dl4
totic activity of the keratinocytes in psoriatic Fig. 2. Time course of transepidermal water loss (TEWL) from 
lesions associated with clinical improvement after day 0 to day 14: (A) of the SDS-exposed skin and the triamcin-
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treatment by topical steroid (7). Furthermore, the 
expression of skin-derived antileukoproteinase 
(SKALP), an elastase inhibitor which is induced in
olon-treated group versus its vehicle; (B) o f the SDS-exposed 
skin and the tretinoin-treated group versus its vehicle; (C) o f  
the SDS-exposed skin and the calcipotriol-treated group versus 
its vehicle.
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Fig. 3. H&E sections showing the difference between the triamcinolon-treated group versus its vehicle with respect to acanthosis, 
hypergranulosis and perivascular infiltrate. (A) with triamcinolon treated; (B) with vehicle treated.
tures were incubated with la,25-(OH)2-D3, pro­
liferation o f T-lymphocytes was reduced (19). Cal- Materials and Methods
cipotriol is the first vitamin D 3-derivative regis- 24 healthy volunteers with no history of skin dis- 
tered in several European countries. Calcipotriol eases (14 male, 10 female, mean age 31, ranging
from 19 to 57 years) participated in the study, 
entiation of epidermal cells, resulting in improve- After approval of Medical Ethic Committee, in- 
ment of psoriatic skin lesions (20, 21). A side-elTect formed consent was obtained from all subjects, 
of psoriasis treatment with topical calcipotriol is 
skin irritation. A study o f Serup et al. (22) demon­
strated that calcipotriol ointment was a mild irri­
tant of the non-corrosive type, i.e., with no influ­
ence on the skin barrier. The irritant effect of calci­
potriol ointment was also noted in some clinical 200 //I of SDS (0.2%) (w/v), pipetted on the patches 
studies (23, 24). The vehicle of calcipotriol oint- consisting of a 1.5 cm piece of absorbent, non-
ment may be at 
skin irritation.
in part responsible for wove n on a 4 cm2
In this study, we examined the effects of a top-
, which was daily fixed at the same 
site with tape (Fixomull® stretch, Beiersdorf AG, 
icetonide 0.05% Hamburg) to the back of the subjects for 4 h for 5 
cream), a retinoid (tretinoin 0.025% cream) and a consecutive days, from day 0 to day 4. After re­
vitamin D} derivative (calcipotriol ointment) in ir- moval of the patches, 0.5 cm of the cream or oint- 
ritant reactions induced by repeated exposures of ment (about 0.35 0.40 g) was applied daily over 
the skin to SDS. The effects were studied clinically the area of previously SDS-exposed skin, dried at 
(erythema), functionally (TEWL) and immuno- room temperature for 30 min. The cream or oint- 
histochemically using markers of epidermal ment was applied for 7 consecutive days.
The following formulations were used: (i) triam-growth, known as Ki-67 antigen, present in cycling 
cells: involucrin and E-FABP, two terminal differ­
entiation markers (25-27); skin-derived-anti leuko- 
proteinase (SKALP) and cytokeratin 16, two mol- tretinoin cream consisted of cetomacrogol cream; 
ecules associated with hyperproliferation and in- (iv) calcipotriol ointment (Daivonex®, Leo, Dan-
cinolon acetonide (0.05%) cream; (1 1) tretinoin 
(0.025%) cream; (iii) vehicle of triamcinolone and
flammation (8, 28) mark); (v) vehicle of calcipotriol ointment.
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scoring and transepidermal water loss 
(T E  W L) measurements
Visual grading and TEWL were assessed at: day 1 
to day 7, day 10 and day 14. TEWL was measured 
with a Tewameter™ 210 (Courage & Khazaka, 
Cologne), according to standard guidelines (29). 
Room temperature varied from 20°C to 25°C and 
relative humidity from 40% to 60%. Clinical scor­
ing (erythema) was graded visually: 0, no response; 
1, slight, patchy redness; 2, diffuse mild redness; 
3, moderate redness; 4, intense redness; 5, intense 
redness with edema.
Biopsy procedures
A total of 40 punch biopsies (3 mm diameter) 
were taken: 16 biopsies at day 2 to examine the 
histology of the triamcinolon-treated group, the 
tretinoin-treated group, the vehicle-treated group
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Fig. 5. Immunohistochemical stainings of the tretinoin -treated 
group versus its vehicle. The results of (B) and (C) are expressed 
as a % of the positive stained-cell layers of the total epidermal 
cell layers. The values are mean±SEM: (A) number of prolifer­
ative cells per mm length section; (B) involucrin expression; (C) 
E-FABP expression.
and the SDS-exposed group; 24 biopsies at day 
4 for these 4 groups and the calcipotriol-treated 
group and its vehicle. Thus, 4 biopsies per treat­
ment/per timepoint. After 4 h fixation in form­
alin, the samples were embedded in paraffin, and 
sectioned at 6 pm  for immunohistochemical 
staining.
Immunohistochemical methods
The biopsies were stained with the following 
antibodies according to standard procedures, de-
ies (4): (i) MIB-1 (Immu-
A. Marseilles
Ki-67 antigen on formalin
material; (ii) MON-150. which
Fig, 4. Immunohistochemical stainings of the jriamcinolon- volucrin, a structural precursor protein for the
formation of the cornified envelope, is described_  .  ( Q
expressed as a % of the positive stained-cell layers of the total 
epidermal cell layers. The values are mean±SEM: (A) number 
o f proliferative cells per mm length section; (B) involucrin ex­
pression; (C) E-FABP expression.
and prepared previously (30); (iii) Anti E-FABP,
mal
rabbit antiserum 
d binding pro te which is associ-
EFFECTS ON SDS-INDUCED SKIN IRRITATION
ated with terminal •entiation (kindly pro- nim length of section. The expression o f involucrin
vided by Siegenthaler (26, 27); (iv) Anti SKALP/ and E-FABP was similarly scored: at a representa-
elafin, a polyclonal antiserum directed against re- tive interpapillary area, the ratio o f positively
combinant SKALP/elafin is prepared as we de- stained cell layers and the total number of cell
scribed previously (8, 9); (v) Ks8.12 (Sigma, St layers, were calculated.
Louis, MO, USA) was used to detect cytokeratin 
16 which is expressed in suprabasal layers in the 
hyperproliferative tissues (28); (vi) H&E accord­
ing to Mayer. The Student /-test and the Wilcoxon test were used
when appropriate.
His to Iogi cal exam in a ti on
We quantified the number proliferative cells by 
counting the number of MIB-1 -positive nuclei per
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Results
Clinical grading and TEWL measurements
Repetitive exposure of human skin to SDS (0.2%) 
induced an increase in erythematous reaction (Fig. 
1) and in TEWL measurement (Fig. 2), enhancing 
in intensity up to day 4, then gradually decreasing 
to day 14. No significant difference in erythema 
or in TEWL was found between the triamcinolon 
acetonide, tretinoin or calcipotriol treated groups 
versus their vehicles.
Histology and immunohistochemistry
H&E staining. The exposed skin of day 4 showed 
mild to moderate parakeratosis, hypergranulosis, 
acanthosis, exocytosis and moderate perivascular 
infiltrate composed of mostly mononuclear cells 
and some eosinophils. The sections of the triamci­
nolon acetonide cream treated skin demonstrated 
a slightly milder perivascular infiltrate, less para­
keratosis and less acanthosis as compared to its 
vehicle (Fig. 3). No difference between the tretinoi- 
n- or calcipotriol-treated skin and their vehicles 
was observed with respect to hypergranulosis, pa­
rakeratosis, spongiosis, acanthosis and perivas­
cular infiltrate.
proliferation. The response of un­
treated skin, repetitively exposed to SDS, was 
characterized by an increase in the number of 
MIB-1 -positive nuclei from 78±22 per mm
a maximum of 180±50 
4 after stimulation. The(mean
number of proliferative cells of all 
groups was also enhanced up to day 4. A
mar cuit (/;==().02) in
number of cycling cells/mm (72±14) of the tri­
amcinolon acetonide treated sections was ob­
served as compared to the other exposed sites 
(Fig 4a). No significant difference in the number 
of cycling cells/mm between the tretinoin- or cal-
Fig. 6. immunohistochemical stainings of the calcipotriol- cipotriol-treated groups versus that with their ve-
treated group versus its vehicle. The results of (B) and (C) are 
expressed as a % of the positive stained-cell layers o f the total 
epidermal cell layers. The values are mean±SEM: (A) number 
of proliferative cells per mm length section; (B) involucrin ex­
pression; (C) E-FABP expression.
hides, was seen (Figs. 5a, 6a).
Epidermal differentiation. To study the effect of 
the verum drugs on epidermal differentiation in 
our model, we investigated the expression of invol-
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Fig. 7. Histological series demonstrating the difference in the number of cycling cells/mm (A and B) and in the involucrin e x p r e ss io n
{A, C) with trimacinolon treated. (B, D) with vehicle trea ted .
respectively.
ucrin and E-FABP. Repetitive application of SDS 
caused an increase in the expression of involucrin, 
and an increase in the expression in E-FABP. At 
day 4, a small decrease in involucrin expression of 
borderline significance 09=0.09) and a non-sig­
nificant decrease in E-FABP expression (/;=0.25), 
were found in the triamcinolon acetonide-treated 
group versus its vehicle (Fig. 4b, c). There was no 
difference in the expression of involucrin and E-
shown).
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expression of the triamcinolone-treated group ver- Calcipotriol did not lead to modulation of the epi-
sus its vehicle are illustrated in Fig. 7.
Discussion
dermal response after exposure to SDS with the 
exception of an increase in TEWL. This may be 
due to its vehicle, which is known to be irritant.
At day 5 after challenge, a small, non-significant
The induction of irritant reactions by repetitive ex- increase (/?=0.18) in TEWL of the vehicle of calci-
posure to SDS and the repair with or without potriol-treated sites versus the SDS exposed sites
treatment were studied using visual scoring, was found. In our present study, repetitive ex-
TEWL and markers of epidermal proliferation posure to SDS for 5 days induced an increase in
and differentiation. Repetitive exposure to SDS number of cycling cells and the expression of invol-
causes an increase in erythema and in TEWL to a ucrin and E-FABP. Treatment with retinoic acid or
maximum at day 4, then gradually decreases up calcipotriol in this irritant skin did not show any
to day 14 after the first challenge. The repetitive alteration with respect to these parameters.
exposure to SDS not only induced histological Topical steroids may influence irritant reactions.
changes to the epidermal cell compartment (para- Skin may deal with repetitive irritant stimuli with
keratosis, perivascular mononuclear infiltrates) adaptation, regeneration or disease (irritant con-
but also upregulated the expression of markers of tact dermatitis). Intervention may influence the in-
epidermal differentiation and proliferation, corre- flammatory response (7) and consequently may
sponding to a hyperproliferative skin. Treatment prevent tissue damage as caused by the inflam-
of skin irritation by triamcinolon acetonide, reti- mation, but may also hamper repair processes by
noic acid or calcipotriol did not improve the clin- its anti-mitotic activity. Therefore, it cannot be
ical scores in this model. Neither significant de concluded from our data that topical steroids are
crease in erythema scoring nor decrease in TEWL beneficial to the skin.
was observed. In contrast to this clinical finding, Single exposure tests are inadequate for predic-
we found a statistically significant reduction of the tion of the effect of treatment modalities. Cumula- 
number of cycling cells in the triamcinolone- tive exposure models or clinical studies with stan- 
treated skin sites versus the other exposed sites. In dardized exposure are needed.
addition, the expression of involucrin and E-FABP 
was also downregulated in the triamcinolon- 
treated skin as compared to that treated with its 
vehicle.
The fact that triamcinolone acetonide cream in­
duces a reduction of cycling cells may indicate that 
triamcinolon acetonide cream causes less irritation 
or delays repair. In contrast to other studies (31, 
32) in which topical steroids are believed to be 
diminish the erythematous response of SDS ex­
posed skin, we could neither demonstrate this ef­
fect in this model nor in a previous work (33).
Treatment with retinoic acid did not lead to any 
change in visual scoring, TEWL and modulation 
of the epidermal response to SDS, as compared to 
its vehicle. Adding retinoic acid to keratinocytes in 
vitro reduces transglutaminase activity and conse-
quently may inhibit terminal 
concomitant cor
srentiation and
envelope formation (34). 
Retinoic acid can induce epidermal hyperprolifer­
ation and increase in transglutaminase immuno- 
reactivity when applied topically for 4 months to 
photoaged human skin (35). Furthermore, retinoic 
acid can increase the expression of transglutamina­
se, loricrin, involucrin, filaggrin when applied to 
normal human skin for 4 days under occlusion 
(36). Here, we found no alterations in involucrin- 
and E-FABP-expression at the tretinoin-treated 
sites. The exact mechanism of retinoic acid in the 
SDS-induced skin irritation remains unknown.
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